RXDX
Sector: Manufacturing
Industry: Pharmaceutical Products
(%)
Volume:
52 week range:
-
Market Cap:
8.120B
Company Description:
PRA023, a humanized IgG1 monoclonal antibody (mAb) is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease. The company also develops PR600, an anti-tumor necrosis factor mAb for IBD; PR300, a G-protein coupled receptor modulator small molecule.